Jaguar Health
Open
$2.67
Prev. Close
$2.70
High
$2.69
Low
$2.67
Market Snapshot
$287.13K
-0.0
-188.60
$11.69M
47
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 47 full-time employees. The company went IPO on 2015-05-13. The firm is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. The company has an exclusive distribution agreement for the sale of Gelclair. The company is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 47 full-time employees. The company went IPO on 2015-05-13. The firm is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. The company has an exclusive distribution agreement for the sale of Gelclair. The company is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
Recently from Cashu
Jaguar Health Advances Rare Disease Therapies, Focusing on Microvillus Inclusion Disease Treatment
Jaguar Health (Ticker: JAGX) is making significant strides in the realm of rare disease therapies, particularly focusing on the ultra-rare condition known as microvillus inclusion disease (MVID). Unde…
Jaguar Health Targets Rare Disease Treatment with Crofelemer Amid Significant Licensing Deal
Jaguar Health (Ticker: JAGX) is at a critical juncture as it zeroes in on the treatment of rare diseases, especially microvillus inclusion disease (MVID). This strategic focus is underpinned by a subs…
Regulatory Changes Propel Innovation in Autonomous Vehicles and Healthcare Solutions
Regulatory Shifts Enhance Autonomous Vehicle Landscape In a significant development for the future of mobility, the National Highway Traffic Safety Administration (NHTSA) proposes amendments to the Fe…
Jaguar Uranium Corp. Unveils Aggressive 2026 Exploration Strategy in Argentina and Colombia
Jaguar Uranium Corp. Moves Forward with Aggressive Exploration Strategy for 2026 Jaguar Uranium Corp. outlines an ambitious exploration strategy aimed at bolstering its uranium portfolio across Argent…